Martin C. Michel European Urology Supplements

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Rodolfo Montironi,

Management of Acute and Chronic Retention in Men

Management of the Urologic Sepsis Syndrome

Bladder Cancer: Management and Future Directions

Let the Games Begin (with EAU Approval)

Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi,

Cholinergic Innervation and Muscarinic Receptors in the Human Prostate

Bladder Cancer: A Major Public Health Issue

Back to the Future: Introduction and Conclusions

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers

A Novel Treatment of Premature Ejaculation

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Functional Bladder Problems

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Richard C. Harkaway European Urology Supplements

Tim Schneider European Urology Supplements

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Transurethral Resection of the Prostate

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

The Importance of Testosterone Control in Prostate Cancer

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Jacques Irani European Urology Supplements

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

The Hallmarks of BPH Progression and Risk Factors

Sergio Bracarda European Urology Supplements

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Pharmacotherapy in Stress and Mixed Incontinence

Christian Stief European Urology Supplements

European Urology is “Your” Journal

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Preclinical Profile of Zoledronic Acid in Prostate Cancer Models

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

Martin Michel, Jean de la Rosette European Urology Supplements

The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

Stone Disease European Urology Supplements

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

LUTS and Sexual Dysfunction: Implications for Management of BPH

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation Martin.

The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study Bob Djavan,

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects Martin C. Michel, Cees Korstanje, Walter.

Beyond Skeletal-Related Events

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Classification of Mixed Incontinence

The Impact of Premature Ejaculation on Partners and Relationships

Diagnosis and Management of Cryptorchidism

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

Epidemiology and Demographics of Prostatitis

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal European Urology.

Presentation transcript:

The Pharmacological Profile of the α1A-Adrenoceptor Antagonist Silodosin Martin C. Michel European Urology Supplements Volume 9, Issue 4, Pages 486-490 (July 2010) DOI: 10.1016/j.eursup.2010.03.006 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Affinities of prazosin, silodosin, and tamsulosin at cloned α1-adrenoceptor subtypes as reported by two independent laboratories. Note that a high graph indicates a high affinity on a logarithmic scale. Adapted from Shibata et al. [9] and Tatemichi et al. [12]. European Urology Supplements 2010 9, 486-490DOI: (10.1016/j.eursup.2010.03.006) Copyright © 2010 European Association of Urology Terms and Conditions